Table 1.
The characteristics of included RCTs of Xuesaitong soft capsule for UA.
| Study ID | Sample (T/C) | Diagnosis standard | Age | Intervention group | Control group | Course (week) | Outcome measures |
|---|---|---|---|---|---|---|---|
| Xiong et al., 2006 [13] | 89/79 | 1979 ISFC/WHO |
37–68 | XST + conventional drugs | Conventional drugs | 8 | FAA, and DAA |
| Du and Chen, 2009 [14] | 56/56 | 2002 ACCF/AHA |
58.8 ± 9.2 | XST + conventional drugs | Conventional drugs | 4 | FAA, DAA, and adverse event |
| Yu, 2010 [15] | 50/50 | 2002 ACCF/AHA |
64.18 ± 12.13 | XST + conventional drugs | Conventional drugs | 4 | RAS, ECG, adverse event, and Followup |
| Ge and Zhao, 2010 [16] | 48/48 | 1979 ISFC/WHO |
53 ± 2 | XST + conventional drugs | Conventional drugs | 4 | RAS, ECG, and adverse event |
| Kong and Zhang, 2006 [17] | 30/30 | 1979 ISFC/WHO |
36–77 | XST + conventional drugs | Conventional drugs | 4 | RAS, ECG, and FAA |
| Wei, 2010 [18] | 90/90 | 1979 ISFC/WHO |
60.4 ± 3.5 | XST + conventional drugs | Conventional drugs | 4 | RAS, ECG, FAA, DAA, and adverse event |
T/C: treatment group/control group; XST: Xuesaitong soft capsule; RAS: reduction of angina symptoms; FAA: frequency of angina attack; DAA: duration of angina attack.